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Abstract
The study aims to systematically extract and analyse data about Quality of Life (QoL) in the transgender population. A systematic
literature search and meta-analysis were conducted using the MEDLINE, EMBASE, PubMed, and PsycINFO databases, up to
July 2017. Only English language quantitative studies, in adults, which reported the means for validated QoL measures were
included. Random-effect meta-analysis was adopted to pool data and estimate the 95% Confidence Intervals (CI). From 94
potentially relevant articles, 29 studies were included within the review and data extraction for meta-analysis was available in 14
studies. The majority of the studies were cross-sectional, lacked controls and displayed moderate risk of bias. Findings from the
systematic review suggested that transgender people display poor QoL, independent of the domain investigated. Pooling across
studies showed that transgender people report poorer mental health QoL compared to the general population (−0.78, 95% CI =
−1.08 to −0.48, 14 studies). However, meta-analysis in a subgroup of studies looking at QoL in participants whowere exclusively
post-CHT found no difference in mental health QoL between groups (−0.42, 95% CI = −1.15 to 0.31; 7 studies). There was
insufficient data for a pre-treatment subgroup. Evidence suggests that transgender people have lower QoL than the general
population. Some evidence suggests that QoL improves post-treatment. Better quality studies that include clearly defined
transgender populations, divided by stage of gender affirming treatment and with appropriate matched control groups are needed
to draw firmer conclusions.
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1 Introduction
The term transgender (or trans) describes people whose gen-
der identity differs from the sex they were assigned at birth
based on their sexual characteristics, whilst the appellation
cisgender refers to any individual who is not transgender
and whose gender identity matches the sex assigned at birth
[1]. Due to the mismatch between gender identity and sex
assigned at birth, many transgender people experience severe
distress, generally known as gender dysphoria, which tends to
ameliorate following transition to the experienced gender [2].
The process of physical transition consists of different
stages. Guidelines for the assessment and treatment of trans-
gender and gender non-conforming people have been devel-
oped by the World Professional Association of Transgender
Health (WPATH) to facilitate this process (Standards of Care,
SOC) [2]. The SOC aims to describe the different treatments
that transgender people might wish to undergo, known as
Gender Affirming Treatments (GAT), which may include pu-
berty suppression, Cross-sex Hormonal Treatment (CHT),
Chest Reconstructive Surgery (CRS) and Gender Affirming
Genital Surgeries (GAGSs) [2]. Thus, for the present review,
the term ‘treatment’ is also used to describe GAT.
GAT produces bodily changes that impact and alter gender
role and its expression by developing secondary sexual char-
acteristics of the experienced gender in order for the body to
become more congruent with the gender identity of the indi-
vidual [2]. These changes might be sufficient to mitigate the
gender dysphoric symptoms [2] and hence improve the
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individual’s QoL. However, not every transgender person re-
quires gender affirming treatment and the dysphoria may im-
prove through gender social role transition only. Thus, treat-
ment might vary depending on the specific needs of the trans-
gender person seeking treatment [2].
Many transgender people, particularly prior to their physi-
cal transition, face considerable challenges. These challenges
can be physiological (development of some of the secondary
sexual characteristics of the sex assigned at birth), social (lack
of social support, rejection, discrimination, victimisation,
transphobia) [3–12] and psychological (e.g. anxiety, depres-
sion, low self-esteem) [3, 13–16]. All these factors have been
found to have a negative impact on the quality of life (QoL) of
transgender people [17, 18].
QoL is a complex and broad concept. It has been de-
scribed in different ways, such as the quality of one’s life
conditions, one’s satisfaction with life conditions, and as a
combination of life’s conditions and satisfaction [19]. De
Vries and colleagues [20] defined QoL as the individuals’
perceptions of their life satisfaction and happiness that has
an impact on objective and subjective wellbeing. Hence,
QoL measures can be considered as a way of quantifying
the level of functioning and perceived wellbeing of peo-
ple’s lives [17]. The concept of QoL encompasses a range
of different physical and psychosocial domains. Several
factors have been shown to affect QoL in transgender
populations, such as presence or absence of depression
and psychopathology, transitional status (such as the use
of cross sex hormone treatment), levels of social support
and perceived discrimination [6, 21–29].
The literature regarding QoL in transgender people mainly
focuses on four QoL dimensions: voice-related (vQoL); sex-
related QoL; body image-related QoL; and general QoL.
Voice-related QoL can be described as the impact that the per-
ception of one’s own voice, in terms of femininity and mascu-
linity, has on the QoL of the individual [30]. This dimension is
very important for transgender people, as the pitch of the voice
is an important aspect of gender expression and perception [31,
32]. Sex-related QoL is a state of social, physical and mental
wellbeing related to sexual life [33]. This concept refers to the
sexual functioning and general satisfaction with sexual life [34].
Body image-related QoL stems from the notion that experienc-
ing a positive body image is linked with more satisfactory re-
lationships, sexuality, improved well-being and overall general
QoL [35]. Thus, transgender people’s incongruence between
gender identity and bodily characteristics could potentially im-
pact their body satisfaction and as a consequence their QoL
[35–38]. Finally, general QoL describes the overall satisfaction
with life not linked to specific physical health conditions and
which includes subcategories linked to aspects of mental, phys-
ical, and social life [39].
There are mixed results regarding the QoL in the trans-
gender population. While most of the literature suggests that
transgender people have lower QoL compared to the general
population [17], which increases once on CHT or post-
GAGS [28, 40, 41], other studies have not replicated such
findings [42, 43]. These mixed results may be explained by
the lack of homogeneity in the population studies, as well as
by the different types of QoL and measurements used. For
instance, the effect of CHT and genital surgery on the QoL
of transgender people when compared to the general popu-
lation is unclear, as studies often use mixed samples in terms
of treatment status and/or focus onto different states of tran-
sition. The review carried out by Murad and colleagues [27]
suggested that CHT improves QoL, sexual and psychological
functioning as well as gender dysphoria; however these find-
ings are based on low quality evidence and the actual impact
of both medical and social transitions upon QoL needs to be
better understood [44].
Therefore, the primary aim of this this study is to conduct a
critical systematic review and meta-analysis of studies of QoL
in transgender populations and to explore the range of QoL
assessed. The present research also aims to investigate the
impact of CHT by exploring QoL in transgender people at
different stages of gender transition.
Additionally, as there is a lack of understanding of the QoL
domains most relevant to transgender people and of how de-
mographic, psychosocial and treatment-related factors influ-
ence those domains, this review specifically aims to assess the
different dimensions of QoL in transgender populations and
their associated factors.
1.1 Eligibility criteria
Studies were included if they aimed to measure QoL in trans-
gender populations using validated QoL tools. Articles were
eligible for inclusion if they reported a mean QoL score for a
transgender population and were either written in the English
language or had an available translation into English. Both
cross-sectional and longitudinal studies were included and there
was no restrictions on settings. Studies were excluded from this
systematic review if they investigated QoL in transgender chil-
dren (<18 years) as QoL vary with age [45]. Additionally, arti-
cles were excluded if they had fewer than 20 participants as in
small studies there is a high risk of selection bias and a lack of
statistical power [46, 47]. Where different articles utilised the
same database and same measures, the most recent article was
taken into consideration and included within the meta-analysis.
Qualitative studies, case studies, conference abstracts and re-
view articles were also excluded. See Table 1 for summary of
the review’s eligibility process.
1.2 Search strategy
PRISMA guidelines were followed [48] to carry out this re-
view. Ovid (PubMed, EMBASE, PsycINFO) and Medline
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databases were searched from 1946 to July 2017. Terms for
transgender people (Transgender, Transsexual, Gender
Identity Disorders, and Gender Dysphoria) were searched
using the OR function and combined with the terms related
to (Quality of Life, QoL, Life Satisfaction) using the BAND^
operator. Additionally, the reference lists of pertinent articles
were searched to identify any further potential relevant papers.
1.3 Quality assessment
Risk of bias was assessed using an instrument adapted from
Ibrahim et al. [49] as this instrument covered the most rele-
vant criteria to assess risk of bias in descriptive studies.
Criteria were [1] a clear definition of the target population,
[2] adoption of either random, complete or consecutive re-
cruitment or an attempt at recruiting every participant in the
sampling frame, [20] sample as representative of the target
population or the report presents evidence that results can be
generalised to transgender people, acknowledging that most
studies included treatment-seeking transgender people at-
tending gender clinics [3] response rate equal or greater than
70%, [4] adequate sample size with a minimum of 300
participants as smaller sample sizes produce large confi-
dence intervals and less precise results [50, 51] and [5] use
of validated measures. The chosen criteria were evaluated as
providing either a risk of bias (or unclear risk of bias) (1
point) or no risk of bias (0 point). Scores are then summed
and an overall risk of bias rating is created where higher
scores indicate greater risk of bias. Studies were rated as
low risk of bias (++) (when all or most of the criteria were
satisfied), moderate risk of bias (+) (when some of the
criteria were satisfied) or high risk of bias (−) (when either
a few or no criteria were satisfied), as per the NICE [52]
guidelines for risk of bias assessment.
1.4 Data extraction
A data extraction table was used to record authors, date of
publication, country where the study was conducted, partici-
pants’ information (sample sizes, mean age of sample at as-
sessments), information on treatment status, study design,
control group and follow-up (if applicable), QoL measures
used, results, factors associated with QoL and conclusions.
Separate tables were constructed differentiating depending
on the QoL domain investigated.
1.5 Meta-analysis
Mental health-related QoLwas used as the outcome of interest
for the meta-analysis, as it was the most widely reported out-
come and physical QoL is more sensitive to the effects of age
[53]. Themost frequently usedQoLmeasures (e.g. SF-36, SF-
12) do not calculate a total score but calculate separate com-
posite scores for mental and physical health. Generic (i.e. not
condition specific) mental health-QoL scores for all samples
with means and Standard Deviations (SDs) reported were el-
igible for inclusion in the meta-analysis. When the means and
SDs for a cisgender group were provided, these were used as
the comparison in the meta-analysis. Where these were not
available, normative data most applicable to the study country
were obtained from the articles providing validation of the
specific measures adopted and were used as comparison.
Utilisation of normative data as a control might cause meth-
odological concerns, as this might increase effect sizes; how-
ever, to not lose valuable data and to be able to carry out the
meta-analyses, this method was deemed as the best approach.
This approach was adopted for four studies [54–57].
In longitudinal studies, data from the first time point at
which the participants met the age criterion for the review
were used. Where studies reported incomplete results, values
were either manually calculated (e.g. SDs from means) or
authors were contacted to provide the missing data.
A second meta-analysis with a sub-group of studies
reporting data for samples of participants who were exclusive-
ly post-GAGS, and therefore post-CHT, as the big majority of
people undergoing gender affirming surgeries are already on
hormonal treatment, was conducted. Pre-treatment-QoL was
not assessed due to a lack of studies using exclusively pre-
treatment samples. RevMan 5 [58] was utilised to conduct the
meta-analyses.
It was hypothesised that the results would be heteroge-
neous because of differences between studies in the stages of
transition investigated (e.g. mixed samples, pre-CHT, post-
CHT, post-GAGS), in the diverse types of recruitment utilised
(e.g. consecutive, snowballing), in the presence of clinical
Table 1 Criteria for inclusion of studies within the review
Category Criteria
Study population Transgender people
Gender Dysphoria, Transsexualism as well as
previous diagnoses according to
DSM or ICD, or self-defined as transgender
LGBT studies only if describing transgender
people as separate category
All races, ethnicities, and cultural groups
Adults
Sample size At least 20 participants
Study settings All settings
No exclusion criteria based on research setting
Time period Published from 1946 to July 2017
Publication criteria Articles in English
Articles in peer reviewed journal
Study design Observational studies using standardised
measure of QoL.
Cross-sectional or longitudinal designs
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and/or non-clinical individuals within the samples as well as
in the focus onto the different gender identities of the partici-
pants (e.g. transman, transwoman, both). Consequently,
RandomEffectsModels (RAM)with 95% confidence interval
was used for the analyses as it implies that the selected studies
are carried out in diverse populations [59]. I2 statistics were
calculated to examine heterogeneity, which is expressed in
percentages suggesting different degrees of heterogeneity
with 25% indicating low, 50% moderate and above 75% high
[60]. Additionally, Q statistics were calculated to determine
the statistical significance of heterogeneity [61].
1.6 QoL measures used in the review
See Table 2 for a description of the measures used in the
studies to assess QoL. Voice-related QoL was assessed using
the Voice Handicap Inventory (VHI) and the Transgender
Self-Evaluation Questionnaire (TSEQ), sex-related QoL using
the sexual subdomain of the WHOQOL-100 and the King’s
Health Questionnaire (KHQ), body image-related QoL using
the body image-related subdomain of the WHOQOL-100 as
well as the Body Image Quality of Life Inventory (BIQLI),
and generic (non-condition specific) QoL was measured using
the Short Form 36 Health Survey (SF-36), version 2 of the
Short Form 36 Health Survey (SF-36-v2), version 2 of the
Short Form 12 Health Survey SF-12-v2, WHOQOL-100,
WHOQOL-BREF, WHOQOL-BREF-TR or the Subjective
Quality of Life Analysis (SQUALA). See Table 2 for a de-
scription of the measures.
2 Results
A total of 403 studies were identified through database
searches, 288 through Ovid and 115 through PubMed. An
additional 12 articles were selected for inclusion in the review
after screening reference lists of relevant papers. After remov-
ing duplicates, 94 abstracts were screened by the first re-
searcher (AN), which resulted in 43 studies that were read in
full. Of these, fifteen were excluded due to reasons such as
lack of a validated QoL measure (n = 4), of direct measure-
ment of QoL (n = 6), of results reported specifically for trans-
gender people (n = 4) and one study was qualitative. Finally, a
sample of 29 papers was discussed, agreed with the other
researchers (JA and CG) and included within this review.
See Fig. 1 for description of the study’s selection process.
2.1 Study characteristics
The earliest articles included within this review were pub-
lished in 2006 [17, 87] whilst the most recent papers were
published in 2017 [31, 32, 55, 57, 64].
The majority of the studies were conducted in European
countries (n = 20). Three studies were carried out in Spain
[21, 32, 34], in France [22, 23, 66] and in Belgium [43, 65,
83]. Two studies were conducted in Italy [73, 74], UK [69,
70], the Netherlands [20, 35] and Germany [31, 55], whilst
one study was carried out in Switzerland [81], one in
Sweden [64] and one in Turkey [76]. With regard to non-
European countries one study was from Brazil [56], one
from China [54] and the remaining articles were from the
USA (n = 7).
Out of the 29 included articles; a) four explored vQoL
[24, 30, 31, 83], b) four looked at sex-related QoL [34, 73,
74, 81], c) three assessed body image-related QoL [35, 73,
74], and e) 22 studies measured generic (non-condition
specific) QoL [2, 17, 21–23, 42, 43, 54–57, 64–66,
68–71, 73, 74, 76, 81]. With regard to vQoL, the study
by Mora and colleagues [32] measured vQoL with the aid
of a non-validated measure as well as general QoL with a
well-validated tool, thus the article was included in the
subgroup of general QoL. The study conducted by Parola
and colleagues [66] was excluded from the sex-related
QoL domain, as it did not employ a validated measure to
assess sex-related QoL. Studies reporting generic-QoL that
either separated mental and psychological subscales or
provided a total QoL score (e.g. Castellano et al. – 71)
were included in the systematic review. Of the four papers
that measured sex-related QoL, three used the sex-related
facet of the WHOQOL-100 [34, 73, 74] whilst one paper
measured QoL related to incontinency in transgender
women post-GAGS and was included within the sex-
related QoL domain [81]. Finally, with regard to body
image-related QoL, one article used a specific body
image-related QoL measure (BIQLI) [35] whilst the others
used the body image-facet of the WHOQOL-100 [73, 74].
In terms of study design, 22 studies were cross-sectional
[17, 21–24, 30, 34, 42, 43, 54, 55, 57, 65, 66, 68–71, 73,
76, 81, 83] and seven were longitudinal [20, 31, 32, 35, 56,
64, 74], although three of the longitudinal studies [20, 31,
32] only reported cross-sectional data for QoL. Of the 29
included studies, eight compared scores of transgender
people to normative data [17, 21, 34, 42, 43, 64, 65, 68],
and eight compared transgender to cisgender individuals
[21, 22, 30, 31, 69, 70, 74, 81] of which four studies used
a matched comparison group [22, 69, 70, 74]. However for
one matched study [70] the gender identity of the compar-
ison group was unclear. Four articles compared QoL in
transgender women to QoL in transgender men [23, 66,
76, 83]. The majority of studies (n = 23) recruited transgen-
der people through clinical services [20–23, 30–32, 34, 35,
43, 55, 56, 64–66, 68–70, 73, 74, 76, 81, 83]. The remain-
ing five studies recruited participants through opportunity
sampling, word of mouth, flyers, advertisement and
through community outreach [17, 42, 54, 57, 71].
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Table 2 Quality of life measures used in the review
Measure Details
1. Short Form 36 Health
Survey
SF-36
[62, 63]
This tool was developed to measure multiple operational health indicators of QoL [62]. It is
a well-validated international measure of health-related QoL consisting of 36-items
providing scores for two summary components (Physical andMental), which encompass
4 subdomains each. The Physical component includes Physical functioning, Role limi-
tations related to Physical problems, Body pain, whilst theMental component comprises
of Perception of General health, Vitality, Social functioning, Role limitations due to
Emotional problems, and Mental health. The scores range from a minimum of 0 until a
maximum of 100, where higher scores indicate greater functioning and enhanced per-
ception of QoL. The cut-off for the population norm is around 50. The measure was
validated in a wide variety of clinical and non-clinical populations, and it displayed an
internal consistency value of .88 when used with Transgender populations [63].
This tool was employed by six studies reported on within this review [43, 54, 55, 64–66].
2. Short Form 36 Health Survey Version 2
SF-36v2
[67]
This measure was developed out of the SF-36. It includes more up-to-date norms and QoL
domains. It is a standardised, comprehensive and validated QoL measure assessing two
summary scores (Physical and Mental components), which encompass 4 subdomains
each. The Physical component includes Physical functioning, Role-physical, Bodily
pain, General health, whilst the Mental component comprises of Vitality, Social
functioning, Role-emotional, and Mental health. It uses a 5-points Likert-scale ranging
from 1 (poor/true) to 5 (excellent/false). Higher scores represent higher perceived QoL
levels. This measure has also been used and corroborated in an online sample of trans-
gender men displaying a Cronbach’s alpha for reliability ranging
from .93 to .95 [17].
This tool was employed by seven studies reported on within this
review [17, 22, 42, 68–71].
3. Short Form 12 Health Survey Version 2
SF-12v2
[72]
This instrument is a subset of the SF-36. It comprises of two summary component scores
(Physical and Mental), which encompass 4 subdomains each. The former component
includes Physical functioning, Role-physical, Bodily pain, General health, whilst the
latter component refers to Vitality, Social functioning, Role-emotional, and Mental
health. This measure utilises a 5-points Likert-scale ranging from 1 (poor/true) to 5
(excellent/false). Scores range from 1 to 100, with higher perceived QoL represented by
higher scores. This measure was validated and showed a good internal consistency, with
Cronbach’s alphas of .89 for the Physical component summary and of .86 for theMental
component summary [72].
This tool was employed by one study reported on within this review [32].
4. WHOQOL-100
[39]
It is a self-administered, self-rated measure to assess QoL developed by the World Health
Organization QoL group. It has been developed cross-culturally and it maintains excel-
lent psychometric properties and internal consistency. This tool comprises a total of
100-items; 96 measures 24 specific QoL facets, whilst the remaining 4-items estimate
General QoL and Overall QoL. The facets are distributed across 6 domains, such as
Physical health, Psychological health, Independence, Social relationships, Environment,
and Spirituality/Religion/Personal beliefs. In order to investigate the Sexual QoL the
specific Sexual activity facet was measured, whilst to examine Body image-related QoL
the body image facet was assessed. Items are rated on a 5-points Likert-scale ranging
from 1 (very poor/very dissatisfied/not at all) to 5 (very good/very satisfied/extremely).
Higher scores indicate greater reported QoL. The scale’s internal consistency values
have been found to range between 0.65 and 0.93 [39].
This tool was employed by four studies within this review [34, 56, 73, 74].
5. WHOQOL-BREF
[45]
It is a self-rated measure that has been validated in field studies involving approximately 30
languages [27]. It is an abbreviated version of theWHOQOL-100. This tool has 26-items
and uses a 5-points Likert-scale measuring 4 domains (Physical, Psychological, Social
relationships, and Environment). In addition, there are two questions regarding General
QoL and General health. Higher scores indicate greater QoL. Internal consistency values
cross-culturally have been found ranging from .51 to .89 [45].
This tool was employed by three studies within this review [20, 21, 57].
6. WHOQOL-BREF-TR
[75]
The WHOQOL-BREF-TR is a 27-items 5-point Likert-scale measuring four domains
(Physical, Mental, Social and Environmental) in two categories (Perceived QoL in
general and perceived health status). It displays acceptable psychometric properties
when used on the Turkish population (Cronbach’s alpha ranging from .53 to .83) [75].
This is the Turkish version of the WHOQOL-BREF and it was used by one study included
in this review [76].
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2.2 Risk of bias
Risk of bias was evaluated for the 29 studies according to the
criteria stated in Table 1. Only three studies recruited more
than 300 participants [17, 42, 71] and the majority either re-
ported response rates lower than 70% or did not mention this
information (n = 21) thus increasing the risk of sampling bias
[17, 20, 23, 24, 30–32, 34, 35, 38, 42, 43, 54, 55, 64, 65, 68,
70, 74, 81, 83]. Overall, only two studies were rated having a
low risk of bias [22, 69], twenty studies had a moderate risk of
bias [17, 20, 21, 23, 34, 35, 42, 54–57, 64, 65, 70, 71, 73, 74,
76, 81, 83] and seven a high risk of bias [24, 30–32, 43, 66,
68]. See Table 3 for details regarding studies’ quality assess-
ment and risks of bias.
3 Results of the literature review
3.1 Voice-related QoL
Of the four papers describing vQoL, three used a cross-
sectional design [24, 30, 83], whilst one article used a longi-
tudinal design with cross-sectional data for vQoL [31]. There
were no studies looking at pre-treatment transgender people.
Table 2 (continued)
Measure Details
7. Subjective Quality of Life Analysis
SQUALA
[77]
It is a self-administered, self-rated, multidimensional QoL measure. It covers 23 QoL
domains (e.g. Mental well-being, Perceived health, Physical autonomy, Social relations,
Environment) as well as general QoL-related concepts (e.g. justice, freedom, truth,
beauty and politics), which identify internal and external reality of everyday life [78].
The measures’ items need to be rated in importance and satisfaction by the person and
higher scores indicate better QoL. Cronbach’s alpha was not available.
This measure was utilised by one study included within this review [23].
8. King’s Health Questionnaire
KHQ
[79]
This is a validated measure used to assess QoL, and with the aid of specific questions it is
often used to estimate levels of incontinence related-QoL. This is a 29-items Likert-scale
assessing ten domains (general health, physical limitations, personal limitations, social
limitations, role limitations, personal relationships, emotion, symptom severity,
sleep/energy and incontinence) and two categories (QoL and Limitation of daily life).
The QoL category is measured with 20-items using a 4-points Likert-scale ranging from
1 (not at all) to 4 (a lot), whilst the incontinence category is measured with 9 items
ranging from 1 (a little) to 3 (a lot). A change of 5 points is considered to be significant. It
has been validated on a sample of urinary incontinent women with Cronbach’s alpha
values ranging from .73 to .89 [80].
This tool was employed by one study reported on within this review [81].
9. Voice Handicap Inventory
VHI
[82]
This is a validated measure used to self-assess the QoL related to the relative impact of a
person’s voice upon daily activities. It is also used to measure QoL of transgender people
concerning the impact and influence of their voices. The VHI is a 30-items 5-points
Likert-scale ranging from 0 (never) to 4 (always). The items are regularly divided within
three domains; functional (F), emotional (E) and Physical (P). The total score (T) is
achieved by summing up E, F and P, and it ranges from 0 (normal voice) to 120 (severely
affected voice). Scores below 40 represent either mild or absent disability, values be-
tween 40 and 60 reflect moderate disability, whilst scores above 60 represent disability.
Internal consistency value was found to be .95 [82]
This measure has been employed by four studies reported on within
this review [24, 30, 31, 83].
9.Transgender
Self-Evaluation Questionnaire
TSEQ
[84]
This is a standardised, subjective measure of voice handicap and vQoL specifically
developed for transgender people. It is based on the VHI but adapted to the specific
concerns of transgender individuals, such as the impact of masculinity/femininity of
voice. It is a 30-items self-reported 5-points Likert-scale ranging from 1 to 5. A total
score ranging from 30 to 150 is calculated by adding up the 30 items’ scores and lower
scores reflect greater vQoL. The TSEQ was found to have good test-retest reliability
(r = .97) [85]. Cronbach’s alpha was not available.
This tool was adopted by two studies reported on within this review [24, 30].
11. Body Image Quality of Life Inventory
BIQLI
[86]
This is a 19-items 7-points Likert-scale ranging from −3 (very negative effect) to +3 (very
positive effect) that assesses body image-related effects onto 19 different areas of life
including sexuality and emotional well-being. Higher scores imply better body
image-related QoL. Internal consistency was found to be excellent (α = .95).
This tool was used by one study included in this review [35].
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Only one study offered comparisons of transgender people
post-treatment with normative data and reported worse
vQoL for transgender people when compared to controls
[31]. The cross-sectional studies that looked at people post-
treatment (GAGS, CHT, Voice Feminisation Treatment -
VFT) found transgender people to experience voice-related
disability, in that they feel handicapped in everyday life be-
cause of their voice [31, 83]. This could be due to the fact that
hormone therapy for transgender women had not affected on
their voice. Only one study compared people according to
their gender identity; this study by T’Sjoen and colleagues
[83] found that transgender men report better vQoL compared
to transgender women post-GAT. Overall, vQoL appears to be
worse in transgender people, particularly in women, even
post-GAT. See Table 4 for details.
The few studies investigating predictors of vQoL found
increased age of the transgender individual, increased fem-
ininity of the voice [24] and low dihydrotestosterone as
well as high Luteinising Hormone (LH) in the blood [83]
to be factors predictive of a positive vQoL in populations
of transgender women.
3.2 Sex-related QoL
Four studies investigated sex-related QoL by adopting a cross-
sectional design [34, 73, 74, 81]; one offered comparisons
with normative data [34], one compared the transgender group
with a cisgender group matched for experienced gender [73],
one carried out comparisons between transgender men and
transgender women as well as between pre- and post-CHT
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Did not measure 
directly QoL 
Fig. 1 Process of identification of
eligible studies for inclusion
within the review
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Table 3 Risk of bias of studies included in the review
Source Sample
definition
(Inclusion
criteria)
Recruitment
(Random,
complete,
consecutive)
Representativeness
of Sample
(Exclusion criteria
and clinical/non-clinical
populations)
Response
rate
(min 70%)
Sample
Size
(min 300)
Comparison Use of
validated
measures
Quality
rating
1.
Auer et al. (2017) [55]
0 1 0 1 1 1 0 +
2.
Ainsworth & Spiegel
(2010) [68]
1 1 1 1 1 1 0 –
3.
Bartolucci et al.
(2015) [34]
0 0 1 0 1 1 0 +
4.
Başar et al. (2016) [76]
0 0 1 0 1 1 0 +
5.
Bouman et al.
(2016) [69]
UK
0 1 0 0 1 0 0 ++
6.
Cardoso da Silva et al.
(2016) [56]
0 0 1 0 1 1 0 +
7.
Castellano et al.
(2015) [73]
0 1 1 0 1 0 0 +
8.
Colton Meier et al.
(2011) [71]
1 1 0 1 0 1 0 +
9.
Colton Meier et al.
(2013) [42]
1 1 0 1 0 1 0 +
10.
Davey et al. (2014) [70]
0 1 1 1 1 0 0 +
11.
de Vries et al.
(2014) [20]
0 0 1 1 1 1 0 +
12.
Gomez-Gil et al.
(2014) [21]
0 0 1 0 1 1 0 +
13.
Gorin-Lazard et al.
(2012) [22]
0 0 1 0 1 0 0 ++
14.
Gorin-Lazard et al.
(2013) [23]
0 0 1 1 1 0 0 +
15.
Hancock et al.
(2011) [30]
0 1 1 1 1 1 0 –
16.
Hancock et al.
(2016) [24]
1 1 0 1 1 1 0 –
17.
Hoy-Ellis et al.
(2017) [57]
USA
0 1 1 0 1 1 0 +
18.
Kuhn et al. (2009) [81]
0 0 1 1 1 1 0 +
19.
Lindqvist et al.
(2017) [64]
Sweden
1 0 0 1 1 0 0 +
20.
Manieri et al.
(2014) [74]
0 0 1 1 1 1 0 +
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[74] and the fourth study compared QoL linked to inconti-
nence in transgender people post-GAGS to twenty members
of the clinical staff who underwent at least one previous ab-
dominal or pelvic operation [81]. This last study was included
within this section as it is linked to surgery outcomes and to
satisfaction with sexual life.
Only one study looked at a transgender sample pre-GAGS
and found that transgender people report worse sex-related
QoL than the general population [34]. Studies including peo-
ple post-GAGS suggested that transgender people still expe-
rienced lower sex-related QoL than their matched controls
[73, 81]. When looking at gender differences, Castellano et
al. [73] suggested that, at post-GAGS, transgender women did
not display significantly different sex-related QoL compared
to cisgender women, whilst transgender men showed lower
sex-related QoL than cisgender men. Instead, studies compar-
ing transgender people according to gender identity reported a
significantly lower sex-related QoL in transgender men when
compare to transgender women, independently of the transi-
tional status [34, 73]. Only one study described changes in
sex-related QoL using a longitudinal methodology [74]. This
study found a significant improvement in sex-related QoL for
both transgender men and transgender women post-CHT [74].
Overall, it appears that sex-related QoL improves post-GAT.
However, such appears to be poor, particularly in transgender
men when compared to cisgender men. See Table 5 for details.
Regarding predictors of sex-related QoL, CHT [34], low
LH in the blood [73], having a partner and experiencing less
negative mood symptoms [34] have been found to be factors
associated with more positive sex-related QoL.
3.3 Body image-related QoL
Three papers described body image-related QoL, however none
of these studies investigated QoL pre-GAT [35, 73, 74]. The
cross-sectional study conducted by Castellano et al. [73] found
no difference in body image-related QoL between the transgen-
der sample post-medical treatments and a matched cisgender
sample. The two longitudinal studies reported an improvement
in body image-related QoL after treatment, specifically after
CHT [74] and mastectomy for transgender men [35]. This sug-
gests that gender affirming treatments are of benefit to body
image-related QoL in transgender samples. The limited re-
search in this area shows that body image related QoL improves
post-GAT. See Table 6 for details.
Table 3 (continued)
Source Sample
definition
(Inclusion
criteria)
Recruitment
(Random,
complete,
consecutive)
Representativeness
of Sample
(Exclusion criteria
and clinical/non-
clinical populations)
Response
rate
(min 70%)
Sample
Size
(min 300)
Comparison Use of
validated
measures
Quality
rating
21.
Meister
et al. (2017) [31]
Germany
1 0 1 1 1 1 0 –
22.
Mora et al. (2017) [32]
Spain
1 0 1 1 1 1 0 –
23.
Motmans et al.
(2012) [65]
0 0 1 1 1 1 0 +
24.
Newfield et al.
(2006) [17]
1 1 0 1 0 1 0 +
25.
Parola et al. (2011) [66]
0 1 1 1 1 1 0 –
26.
T’Sjoen et al.
(2006) [83]
0 0 1 1 1 1 0 +
27.
van de Grift et al.
(2016) [35]
0 0 1 1 1 1 0 +
28.
Wierckx et al.
(2011) [43]
0 1 1 1 1 1 0 –
29.
Yang et al. (2016) [54]
0 1 0 1 1 1 0 +
0 =No risk of Bias; 1 = Risk of Bias; ++ = Low Risk of bias; + =Moderate Risk of Bias; − =High Risk of Bias
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Only one study looked at factors associated to body image
quality of life and found low levels of LH in the blood to be
associated to a positive body image-related QoL [73].
3.4 General (non-condition specific) QoL
Out of the 22 studies that assessed generic (non-condition
specific) QoL, there were no cross-sectional studies looking
specifically at people pre-GAT. Five studies investigated post-
GAT [20, 43, 66, 68, 73], twelve were mixed in term of treat-
ment status [17, 21–23, 42, 54, 55, 65, 69–71, 76], three were
longitudinal [56, 64, 74], one did not report information on
treatment status [57] and one study reported only that partic-
ipants were pre-facial feminisation treatment [32].
There is pre-CHT data available from the longitudinal stud-
ies showing that transgender people have lower QoL than the
general population [56, 74]. Of the six cross-sectional studies
looking specifically at people pre-GAGS [21–23, 54, 68, 71],
two studies found transgender people to report poorer QoL than
the general population [21, 68] and one found similar scores to
their matched cisgender controls [22]. The remaining studies
did not include comparisons with the general population but
they suggested that transgender people report poor QoL.
Five studies investigated QoL at post-GAGS; four studies
found that transgender people at this stage still report lower
QoL than the general population [43, 66, 68] whilst two stud-
ies suggested transgender people to display similar QoL to the
general population [20, 73].
With regard to mixed samples, one study suggested trans-
gender people report worse QoL than their matched cisgender
controls [69], two reported poorer QoL than the cisgender
non-matched controls [21, 70] and one study suggested worse
QoL than the general population [65]. Studies looking at peo-
ple according to their gender found that some of the results
regarding QoL in transgender men were contradictory; one
study indicated that they suffer from worse QoL than the gen-
eral population [17] whilst another study suggested the oppo-
site [42]. Transgender men were also found to report a better
QoL when undergoing CHT than when not on hormones [71].
Instead, transgender women displayed high physical health-
related QoL and poor mental-health related QoL [54]. The
remaining three mixed sample studies made comparisons be-
tween transgender men and transgender women, and the re-
sults are inconsistent. Two studies found that transgender
women report better QoL than transgender men [23, 76] and
one found no difference between transgender men and trans-
gender women [55]. In another mixed study, Motmans and
colleagues [65] found that transgender men had worse QoL
than the cisgender population. However the results of the
above mixed sample studies need to be interpreted carefully.
Regarding the three longitudinal studies [56, 64, 74], one
found an improvement in QoL 1-year post-CHT when com-
pared to pre-CHT levels [74]. A different study also found anTa
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improvement in transgender women 1-year post-GAGS when
compare to pre-CHT values [56]. The third study compared
QoL pre-GAGS (on CHT) and 1, 3 and 5-years post-GAGS.
This study found that although QoL pre-GAGS was lower
than the general population it improves 1-year post-GAGS.
However the study also found that it reduces 3 years post-
GAGS and even more 5 years after genital surgery. This could
be explained as the first year post-GAGS is often known as the
Bhoneymoon period^ and people tend to report overly en-
hanced QoL, which are not representative of a long-term pic-
ture of patients’ psychological status and QoL [43]. When
investigating longitudinal results according to gender a study
found that transgender women displayed greater improve-
ments in QoL 1-year post-CHT compared to transgender
men [74].
Overall, the studies investigating general QoL in transgen-
der people found poorer QoL pre-GAT than the general pop-
ulation, which improve after GAT in the short term. See
Table 7 for details.
Medical and surgical treatments (i.e. CHT, CRS, GAGS)
[17, 21–23, 56, 66, 68, 71], post-surgical well-being [20] and
sexual functioning [43], presence of social and family support
[21, 42, 55, 70, 77], decreased depression, anxiety and stress
levels [42, 55], lack of chronic pain symptomatology [55],
hope and resilience [54], high self-esteem and low levels of
interpersonal issues [69], lack of identity stigma [57], having a
good body image and good sleep quality [55], low levels of
LH in the blood [73] as well as being employed and in a
relationship, younger age, higher education, a high household
income [65] and having undergone military service [57] were
found to be factors predictive of a positive QoL.
4 Results of the meta-analysis
4.1 Meta-analysis – Mental health-related QoL
of transgender people compared to the general
population
Measurements of QoL provide information regarding physical
and mental health-related QoL but only a minority of studies
looked at physical health-related QoL; therefore the meta-
analysis focused on mental health-related QoL compared to
those of the general population. Of the 22 studies assessing
general QoL in transgender populations, 14 were considered
suitable for inclusion in the meta-analysis [17, 20–22, 43,
54–57, 64, 65, 68–70]. These studies include people pre-
GAT, post-GAT and mixed groups at different stages of med-
ical transition. Studies were excluded from meta-analysis due
to the absence of the mean, SD and/or sample size [66, 74],
mental health quality of life not reported separately [73], in-
sufficient detail about scoring [32, 42, 71] and the lack of
access to appropriate normative data [23, 76]. Data at pre-
treatment were utilised for the two longitudinal studies includ-
ed in the meta-analysis [56, 64]. Additionally, normative data
as comparison was obtained for four studies [54–57].
The results of the meta-analysis (14 studies) showed that
transgender people report a statistically significantly lower
mental health-related QoL than the general population (stan-
dard mean difference − 0.78, 95% CI = −1.08 to −0.48, Z =
5.16, p < 0.00001). Heterogeneity was high (I2 = 97%, p <
0.00001) (see Fig. 2).
4.2 Meta-analysis – Subgroup analysis – Mental
health-related QoL post-hormonal treatment
of transgender people compared to the general
population
A secondmeta-analysis was conducted with only the 7 studies
that included exclusively post-treatment QoL scores [20, 43,
56, 64, 65, 68, 70]. The longitudinal study of Lindqvist et al.
[64] investigated QoL post-GAGS but as the first time mea-
surement was pre-GAGS and thus post-CHT, this measure
was included in this analysis. Whilst for the longitudinal study
of de Vries et al. [20], values at the latest time-point were used,
as they measured QoL post-CHT in a sample of individuals
older than 17 years of age.
The meta-analysis of 7 studies found that there was no
statistically significant difference in mental –health related
QoL of transgender people following CHT compared to the
general population (standard mean difference = −0.42 CI
95% = −1.15 to 0.31; Z = 1.13; p = 0.26). Heterogeneity was
high (I2 = 98%; p < 0.00001) (see Fig. 3).
5 Discussion
The aim of this study was to systematically and critically
review the literature pertaining to quality of life in transgender
people, to meta-analytically investigate mental-health related
QoL compared to cisgender populations and to investigate the
impact of GAT on the QoL of this population. A total of 29
studies met the inclusion criteria and were used for the sys-
tematic review and, of these, 14 studies were suitable for in-
cluding in the meta-analysis. Most papers in this area investi-
gated general QoL and only a few focused on either vQoL,
sex-related QoL or body image-related QoL. The majority of
these articles displayed either high or moderate risk of bias.
Many studies used transgender samples that are not homoge-
neous in terms of gender affirming medical treatment status,
which makes it difficult to draw firm conclusions about the
impact of GAT.
Findings from the meta-analysis of mental health-related
QoL suggest that the QoL of transgender people is significant-
ly poorer than that of the general population, with a medium to
large effect size (standard mean difference = 0.78). The
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subgroup meta-analysis including only the samples of trans-
gender people who were classifiable as post-hormonal treat-
ment found that transgender people post-CHT still had lower
mental health-related QoL than the general population. This
difference was not significant and the effect size was reduced
(standard mean difference = 0.42). The possibility that treat-
ment is associated with improvements in mental wellbeing is
supported by the findings from the small number of longitu-
dinal studies in this review. These found that both CHT and
GAGS improve QoL [56, 64, 74]. However these results need
to be treated with caution, as the only study to employ a longer
term follow-up [64] reported that after an initial improvement
in QoL at 1-year post-GAGS, scores tend to steadily decrease
in the following years until reaching 5-years post-GAGS,
when QoL is lower than at pre-treatment [64]. During the first
year post-GAGS people tend to report overly enhanced QoL,
which may not be representative of a long-term picture of
patients’ psychological status and QoL [43]. The improve-
ment in QoL experienced by transgender people at short-
term could be attributed to relief at being able to live as the
experienced gender. Additionally, as QoL in the general pop-
ulation has been shown to decrease with age [53], a decline in
these scores is somewhat expected as time passes.
In contrast, the small number of studies that explore general
physical health-related QoL suggest that at post-GAT, trans-
gender people’s reported QoL scores either similar to [22] or
better than that found in the general population [17, 43].
However, only a minority of studies report findings related
to physical health-related QoL and it is difficult to draw accu-
rate conclusions.
5.1 Condition specific QoL
When looking at condition-specific QoL, studies investigating
vQoL reported that CHT has been shown to have a positive
impact on transgender men. This is not surprising, as testos-
terone is known to affect voice by thickening vocal chords and
by decreasing the pitch [87]. On the other hand, studies in
transgender women, including post-voice feminising surgery,
found that they still feel handicapped regarding their voice in
their everyday life, irrespective of the transitional status. In
fact, studies have suggested that the more feminine a trans-
gender person perceives her own voice, the higher the expe-
rienced vQoL [30, 31]. However, these studies are limited by
focusing on transgender women who transitioned post-puber-
ty. This means that by the time they initiated physical transi-
tion, testosterone has already negatively altered their voice.
Thus findings from vQoL cannot be generalised to the overall
transgender population. Future studies should explore differ-
ences in vQoL between those who transitioned pre-puberty
and therefore before the breaking of the voice, and those
who transitioned post-puberty, when the voice has already
been affected.
Fig. 2 Meta-analysis on mental health-related QoL of transgender people compared to the general population
Fig. 3 Meta-analysis on mental health-related QoL transgender people post-hormonal treatment compared to the general population
216 Rev Endocr Metab Disord (2018) 19:199–220
Regarding sex-related QoL, longitudinal studies suggest that
undergoing GAT improves sex-related QoL [74] but the QoL of
transgender men post-GAGS is still worse than that of cisgender
men. However, the articles investigating sex-related QoL in
transgender men did not distinguish whether patients underwent
phalloplasty or metoidioplasty. Surgical treatments help the
transgender person reach the desired physical changes and lead
towards a more congruous body with their gender identity. This
may lead to people feeling more comfortable with their own
bodies and consequently when being intimate with others.
Longitudinal studies also supported an amelioration in body
image-related QoL [35, 74]. In fact, Castellano and colleagues
[73] reported no difference between the transgender population
and their matched controls. This could be due to the fact that
people undergoing GAGS are generally already on CHT and
hormonal treatment is known to have a positive effect on body
image [10, 36, 88] by aiding in the development of desired
secondary sexual characteristics of the experienced gender,
whilst helping to alter some of the attributes relative to the sex
assigned at birth. Consequently, this leads to an improvement in
body image-related QoL. Nonetheless, van de Grift et al. [35]
proposed body image-related QoL to be lower for transgender
people post-CRS, than for the general population. This might be
caused by the fact that following CRS, some people’s genital
dysphoria may increase. However, caution is still needed when
generalising the findings due to the studies’moderate risk of bias
as well as their methodological limitations.
5.2 General QoL
Studies regarding general QoL have found that transgender peo-
ple’s QoL is poorer than that of cisgender people, but that it
improves post-GAT. The poorer QoL found in the transgender
population pre-CHT [56, 74] could be explained by the high
degree of mental health problems reported in this population
[16, 89] aswell as by the difficulties thatmany have in socialising
and living a fulfilling life [10–12, 37]. However, the studies that
focus only on people pre-CHTwere rare and only included those
seeking medical transition, which does not allow for a generali-
sation of these findings to the general transgender population.
When looking at general QoL post-GAT, only a small num-
ber of studies provided control data and none of them had a
low risk of bias. Findings of the subgroup meta-analysis at
post-treatment showed that there is no difference in general
QoL between transgender people and the general population.
The improvement in QoL post-GATcould be due to the effect
of treatment in the reduction of dysphoria and mental health
problems, such as self-harm and depression [13, 90].
Overall, findings support the idea that QoL improves follow-
ing hormonal treatment [74] as well as post-genital surgeries
[43, 56]. As people undergoing surgery are generally already on
hormones, the exact role of genital surgery in QoL cannot be
extrapolated from these studies. Often, even after an
improvement in QoL post-surgical treatment, transgender peo-
ple reported lower QoL compared to cisgender individuals [7,
56, 64, 70]. This could be due to the fact that, even if being
happier with their own bodies, society is still not ready to accept
transgender people; thus work, education or relationships can
be affected by being transgender [6, 91, 92]. This is confirmed
by the findings of studies investigating factors predictive of
QoL in this population, as described in the section below.
Caution is needed while interpreting the results in compar-
ison to cisgender individuals as not all studies have matched
controls and sample sizes are generally small. Additionally, as
the majority of the studies investigated QoL in transgender
clinical populations, generalisation of findings for the general
transgender population is hindered.
Studies on differences between transgender men and trans-
gender women advance contrasting results. Two studies
seemed to suggest that transgender men display lower QoL
compared to transgender women [23, 76], two studies sug-
gested the opposite [21, 66], whilst one study proposed no
statistically significant differences between groups [55].
Literature also suggested that at 2-years post-treatment trans-
gender men display higher QoL than transgender women [66],
whilst still lower than cisgender people [73]. These findings
might be due to baseline differences in QoL scores [65] as
well as because of the utilisation of mixed samples in terms
of treatment status. Results need to be interpreted with caution
as none of the articles displayed a low risk of bias. A possible
explanation for transgender men to report higher QoL than
transgender women might be due to the wider social accep-
tance towards masculinity than femininity. This presents itself
with transgender men reporting less marked psychopathology,
getting involved more easily in society and being employed in
more stable jobs, whilst feeling less limitations in daily life
related to their physical and emotional state [21, 66].
Additionally, studies that reported transgender women to dis-
play higher QoL than transgender men suggested that these
findings are unexpected and surprising [76] considering the
low social status of and amount of discrimination faced by
transgender women in some countries (e.g. Turkey).
5.3 Factors associated with QoL
QoL can be influenced by a wide array of factors, which can
predict both its increment, as well as its decline. Literature
looking at variables associated with a positive QoL for trans-
gender people suggested that undergoing medical and surgical
treatments (i.e. CHT, CRS, GAGS) are the main predictive
factors, irrespective of the QoL domain studied [17, 21–23,
34, 66, 68, 71]. These findings were confirmed by longitudi-
nal studies, which indicated an improvement in QoL from pre-
to post-treatment [35, 56, 74].
Additionally, social and family support, being employed,
being in a relationship, being younger, having a partner, being
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highly educated, having a high household income, and the
presence of past military service were associated with improved
scores on general and sex-related QoL [21, 34, 54, 57, 65].
Instead, anxiety, poor sleep quality, experiencing pain, re-
duced self-esteem and high interpersonal issues are factors that
have been linked to poor QoL in both transgender populations
[22, 42, 55, 69, 70, 76] as well as in the general population [93].
6 Conclusion
As all systematic literature reviews, this study is also limited
by the amount and quality of the published literature available.
Future studies should employ more robust methodologies,
which explore QoL in a more homogeneous population and
using matched control groups.
Despite the limitations of the published literature, this re-
view concludes that overall transgender people display poorer
QoL than the general population, particularly pre-GAT, and
that QoL improves once people are on CHT.
When specifically looking at the different dimensions of
QoL (vQoL, sex-related QoL, and body image-related QoL),
findings of the systematic review suggest that transgender
people display poorer QoL than the general population, inde-
pendent of the QoL domain investigated. As per general QoL,
all dimensions of QoL have been shown to improve post-
GAT. However, as the effect of GAT is linked to gender, a
more positive vQOL was found for transgender men than
transgender women at post-GAT, whilst opposite findings
were obtained for sex-related QoL.
As long-term follow-up studies are limited in numbers and
methodology, more studies are required exploring long-term
QoL. This information may aid the development of support
and interventions aiming at increasing resilience for those at
risk of a poor QoL post-GAT.
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